Clinical Trial Search

Primary: This Outcome Measure is the Tedizolid Area Under the Concentration Time-curve From Time 0 to 72 Hours in Morbidly Obese Subjects and Matched Non-obese Subjects. — 26.0…

Primary: Mean Percent Change in Inflammatory, Non-inflammatory and Total Lesion Counts From Baseline to Week 8. — -78.70; -61.52; -69.32; -77.09 Percent change — p=0.0769

Primary: Mean Change From Baseline in Center for Neurologic Study-Lability Scale (CNS-LS) Score at Day 90 — -7.69; -7.22; -7.59; -8.54 Units on a scale — p=<0.0001

Primary: Number of Subjects With Severe (Grade 3) Unsolicited Adverse Events — 0; 0; 0 Participants

Primary: 2- Hour Pain Relief — 72.5; 69.4; 38.8 percentage of participants

Primary: Recurrence of Cutaneous Abscess — 5; 7 Participants

Primary: Drop-out Rate Caused by Adverse Event After 6 Weeks Treatment — 40.91; 30.16 percentage of participants

Primary: mYPAS Score as Completed by Researchers to Assess Anxiety — 23.3; 36.3 units on a scale

Primary: Number of Patients Requiring Catheterization for Urinary Retention Secondary to Treatment. — 0 participants

Primary: Steroid Levels in Urine Steroid Profile — 69.5773456; 138.0291641; 163.117081; 107.7160658 ng/mL

Primary: Average Blood Glucose Over 6 Days — 174; 174.5 milligrams per deciliter — p=.958

Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 6; 24; 21 Participants

Primary: Frequency of HSV-2 Total Shedding From the Genital Tract as Measured by PCR, Calculated Using a Per-day Shedding Rate in Participants Treated With High-dose Valacyclovir…

Primary: Number of Participants Who Received Influenza Vaccine — 20 Participants

Primary: Change in Attention Assessment — -70.0; -39.7 milliseconds — p=.0492